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Abstract
Background: Human African Trypanosomiasis (HAT) is a protozoan parasitic disease caused by Trypanosoma brucei.
The disease is endemic in regions of sub-Saharan Africa, covering 36 countries and more than 60 million people at
the risk. Only few drugs are available for the treatment of HAT. Current drugs suffer from severe toxicities and require
intramuscular or intravenous administrations. The situation is further aggravated due to the emergence of drug
resistance. There is an urgent need of new drugs that are effective orally against both stages of HAT. Natural products
offer an unmatched source for bioactive molecules with new chemotypes.
Methods: The extracts prepared from 522 plants collected from various parts of the North America were screened in
vitro against blood stage trypamastigote forms of T. brucei. Active extracts were further screened at concentrations
ranging from 10 to 0.4 μg/mL. Active extracts were also investigated for toxicity in Differentiated THP1 cells
at 10 μg/mL concentration. The results were computed for dose–response analysis and determination of
IC50/IC90 values.
Results: A significant number (150) of extracts showed >90 % inhibition of growth of trypomastigote blood forms
of T. brucei in primary screening at 20 μg/mL concentration. The active extracts were further investigated for
dose–response inhibition of T. brucei growth. The antitrypansomal activity of 125 plant extracts was confirmed
with IC50 < 10 μg/mL. None of these active extracts showed toxicity against differentiated THP1 cells. Eight
plants extracts namely, Alnus rubra, Hoita macrostachya, Sabal minor, Syzygium aqueum, Hamamelis virginiana,
Coccoloba pubescens, Rhus integrifolia and Nuphar luteum were identified as highly potent antitrypanosomal
extracts with IC50 values <1 μg/mL.
Conclusions: Limited phytochemical and pharmacological reports are available for the lead plant extracts
with potent antitrypanosomal activity. Follow up evaluation of these plant extracts is likely to yield new
antitrypanosomal drug-leads or alternate medicines for treatment of HAT.
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Background
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is caused by infection with Trypano-
soma brucei. HAT is almost always fatal, if untreated or
inadequately treated, and is a substantial cause of both
mortality and morbidity in affected regions. Infection
with T. brucei also has a substantial effect on livestock
production [1]. The human disease occurs in two forms,
depending on the subspecies of the trypanosome in-
volved. Trypanosoma brucei gambiense causes a chronic
infection that may persist for months or even years
without major signs or symptoms of the disease. Trypa-
nosoma brucei rhodesiense causes an acute infection [2],
where signs and symptoms of the disease are observed a
few weeks after the infective bite. The acute form de-
velops rapidly, soon invading the central nervous system
[3]. Currently, only four drugs are registered for the
treatment of the HAT, which were developed several
years ago. All drugs are toxic and require cumbersome
treatment schedules. Pentamidine is used to treat the
first stage of T. brucei gambiense infection [4]. Suramin
is used to treat the first stage of T. brucei rhodesiense
infection [4]. Intravenous melarsoprol is used in the
second stage of both forms of the disease [5]. On aver-
age, 5 % of patients treated with melarsoprol have a fatal
serious adverse event [6]. Eflornithine is used in the
second stage of T. b. gambiense infection. No new chem-
ical agents have been approved since eflornithine in
1990. A new protocol for the treatment of late-stage T.
brucei gambiense that uses the combination nifurtomox/
eflornithine (NECT) was recently shown to have better
safety and efficacy than eflornithine alone, while being
easier to administer [7]. This breakthrough represents the
only new therapy for HAT since the approval of eflor-
nithine. Toxicity and suboptimal efficacy of currently
available HAT drugs, the growing problem of drug resist-
ance to pentamidine and melarsoprol [8, 9] and severely
depleted antitypanosomal drug discovery pipeline necessi-
tate the discovery of new antitrypanosomal drugs with
better efficacy and safety profiles. Natural products remain
an unmatched source of drugs leads with diverse and
novel chemotypes. About 70 % of the currently available
drugs have their origin from natural products, mainly
from plants. Screening of natural products plant extracts
will promise potential for discovery of new drug leads
[10]. The North American plants have shown significant
medicinal values. However, the plants from this region of
the world have not been explored earlier for new antipara-
sitic and antiprotozoal drug discovery. This study presents
the results on screenings of the extracts prepared from the
plants collected from this region for discovery of new nat-
ural products drug-leads and alternate medicines from
traditional natural products sources for treatment of
human African trypanosomiasis. Trypansoma brucei
brucei strain 427 a non-human sub specie, which has
been extensively used for molecular and biochemical
investigations on trypanosomes and compounds screen-
ing, was employed for the screening [11, 12].
Methods
Plant collection
Botanists at the Missouri Botanical Garden, St. Louis,
Missouri (MOBOT) collected the plants the plants from
different parts of North America, under a cooperative
scientific agreement with the National Center for Natural
Products Research. The information on NPID (a unique
identification number), sample name, code, genus, species,
family, source, common name, plant part, geographical
location, collector and collector’s number are given in the
supplement Table (Additional file 1: Table S1).
Extraction procedure
Bulk plant samples are dried and frozen in the field and
freeze dried at the University of Mississippi before ex-
traction. The freeze-dried plant materials were extracted
with Dionex ASE 300. Extraction was done in 95 % etha-
nol. Each sample was placed in a specific ASE cell and
extracted at 1500 psi, at 40 °C for 3 times with 10 min
static time/extraction. ASE cells were purged for 120 s.
After extraction the extracts were dried and dissolved in
DMSO at a concentration of 20 mg/mL.
Culture maintenance
Blood stage forms of Trypanosoma brucei brucei
(bloodstream form, Strain 427 obtained from Frederick S.
Buckner, Department of Medicine, University of
Washington, Seattle, Washington, USA) was grown in
IMDM medium supplemented with 10 % fetal bovine
serum. The culture was maintained at 37 °C in 5 %
CO2 incubator. THP1 cells obtained from ATCC were
grown in RPMI 1640 medium supplemented with
10 % fetal bovine serum. The culture was maintained
at 37 °C in 5 % CO2 incubator.
Antitrypanosomal assay
A 2 days old culture of T. brucei brucei in the exponential
phase was diluted with IMDM to 5000 parasites/mL. Max-
imum permissible limit of DMSO in the assay was 0.5 %.
The assays were set up in clear 96 well microplates. For
primary screening (Single concentration of 20 μg/mL in du-
plicate) extract dilutions (1 mg/mL) were prepared from
the stock extracts (20 mg/mL) in IMDM medium. Each
well received 4 μL of diluted extract sample and 196 μL of
the culture volume (total culture volume 200 μl). The plates
were incubated at 37 °C in 5 % CO2 for 48 h. Alamar blue
(10 μl) (AbD Serotec, catalog number BUF012B) was added
to each well and the plates were incubated further for over-
night. Standard fluorescence was measured on a Fluostar
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Galaxy fluorometer (BMG LabTechnologies) at 544 nm
excitation, 590 nm emission. Pentamidine and α-
difluoromethylornithine (DFMO) were tested as standard
(Table 1). The extracts that have shown more than 90 %
inhibition of T. brucei growth in primary screening were
subjected to secondary screening for dose–response ana-
lysis. Active extracts were screened at concentrations ran-
ging from 10 – 0.4 μg/mL. IC50 and IC90 values were
computed from dose response growth inhibition curve by
XLfit version 5.2.2.
Cytotoxicity assay
The extracts were also tested for cytotoxicity against
transformed human monocytic (THP1) cells. A 4 days’
old culture of THP1 cells in the experimental phase was
diluted with RPMI medium to 2.5X 105 cells/mL. Phorbol
12-myristate 13-acetate (PMA) was added to the culture
at 25 ng/mL concentration for transformation of the cells
to adherent macrophages [13]. The PMA treated THP1
cell culture was dispensed in 96 well plates with 200 μl
culture (2.5X 105 cells/mL) in each well and plates were
incubated at 37 °C in 5 % CO2 incubator for overnight.
Extracts were diluted in separate plates (Daughter plates)
in RPMI medium. The medium in plates with THP1 cells
was replaced with fresh medium. The diluted plant ex-
tracts were added to these plates. The plates were placed
again in CO2 incubator at 37 °C, 5 % CO2 for 48 h. After
48 h 10 μl of alamar blue solution was added to each well
and the plates were incubated further for overnight.
Standard fluorescence was measured on a fluorometer at
544 nm ex, 590 nm em. Cytotoxicity screening was done
for active extracts, which have shown more than 90 %
Table 1 In vitro antitrypanosomal activity of the most active plant extracts against Trypanosoma brucei
NPID Sample name Family Common name Plant part IC50 (μg/mL) IC90 (μg/mL)
81880 Alnus rubra Betulaceae Red alder BK 0.94 ± 0.58 1.95 ± 0.17
81890 Boykinia major Saxifragaceae Large Boykinia RT 2.82 ± 0.44 8.31 ± 1.50
81897 Juniperus communis Cupressaceae Juniper LF-ST 2.40 ± 0.44 6.66 ± 2.13
81908 Chrysolepis chrysophylla Fagaceae Golden chinquapin FL 2.89 ± 0.40 7.31 ± 1.57
81925 Rhododendron occidentale Ericaceae Western azalea LF 2.87 ± 0.43 6.88 ± 1.16
81940 Arctostaphylos viscida Ericaceae Whiteleaf manzanita, sticky manzanita LF 2.88 ± 0.21 5.96 ± 1.09
81953 Eriogonum umbellatum Polygonaceae Buckwheat LF-ST 2.79 ± 0.34 6.25 ± 1.94
82438 Eriogonum fisciculatum Polygonaceae California or Eastern Mojave buckwheat LF 2.68 ± 0.44 7.73 ± 2.33
82440 Rhus integrifolia Anacardiaceae Lemonade berry LF 2.97 ± 0.01 4.41 ± 0.29
82453 Hoita macrostachya Fabaceae Large leatherroot LF 0.48 ± 0.00 0.62 ± 0.00
82466 Lepechinia calycina Lamiaceae Pitcher sage; woodbalm LF 2.50 ± 0.05 5.04 ± 0.12
82467 Ribes speciosum Grossulariaceae Fuchsia-flowered gooseberry LF-ST-FL 2.95 ± 0.10 5.90 ± 0.08
82468 Salvia spathacea Lamiaceae Pitcher or hummingbird sage ST 1.13 ± 0.78 3.46 ± 0.34
82484 Sabal minor Arecaceae Bush palmetto FL 1.06 ± 0.44 2.07 ± 0.96
83334 Medinilla magnifica Melastomataceae Chandelier tree FL-FR 2.25 ± 1.16 7.89 ± 2.48
83345 Eucalyptus citriodora Myrtaceae Lemon-scented gum LF 2.91 ± 0.21 5.82 ± 0.04
83360 Acer rubrum Sapindaceae Red maple LF 2.88 ± 0.50 7.45 ± 0.70
84470 Ligustrum sinense Oleaceae Privet LF-FR 2.77 ± 0.40 4.41 ± 1.46
84516 Hamamelis virginiana Hamamelidaceae Witch hazel ST 2.54 ± 0.53 4.65 ± 3.92
84686 Lyonia fruticosa Ericaceae Coastal plain staggerbush ST 2.54 ± 0.71 4.65 ± 3.92
84709 Ribes montigenum Grossulariaceae Gooseberry-currant ST 1.94 ± 0.67 7.39 ± 2.74
84712 Quercus alba Fagaceae White oak BK 1.42 ± 0.30 7.53 ± 0.44
84715 Leea rubra Vitaceae West Indian holly, red leea ST 1.62 ± 0.32 4.50 ± 1.04
84720 Coccoloba pubescens Polygonaceae Grandleaf seagrape ST 0.83 ± 0.04 1.91 ± 0.16
84722 Rhus integrifolia Anacardiaceae Lemonade berry ST 0.50 ± 0.10 1.07 ± 0.33
84738 Nuphar luteum Nymphaeaceae Water lilly FR 0.42 ± 0.02 1.32 ± 0.11
131665 Difluoromethylornithine 5.07 ± 0.27 12.37 ± 0.96
103650 Pentamidine 0.002 ± 0.001 0.003 ± 0.001
(A complete list of plants screened is presented as supplement material –Additional file 1: Table S1 and Table S2) NPID- Natural Product Identification Details
(accession number); Plant parts- BK- stem bark; LF- leaves; FL- flowers; ST- stem; FR- fruit; IC50 and IC90 values are mean ± SD
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inhibition in primary T. brucei screening. None of the T.
brucei active plant extracts have shown more than 50 %
inhibition on differentiated THP1 cells at 10 μg/mL
concentration.
Results and discussion
The primary screening for T. brucei was done for ex-
tracts prepared from 522 plants collected from various
parts of the North America (Additional file 1: Table S1).
A significantly high number (150 extracts) of extracts
showed >90 % inhibition of growth and proliferation of
trypomastigote forms of T. brucei at 20 μg/mL. Second-
ary screening was done for active extracts at concentra-
tions ranging from 10 – 0.4 μg/mL (Additional file 1:
Table S2) and we identified ten plants extracts with po-
tent antitrypanosomal activity with IC50 values <2 μg/
mL (Table 1). Antitrypanosomal activity of these plants
extracts was selective as none of these were significantly
active against Leishmania donovani, Plasmodium falcip-
arum (unpublished data) and transformed THP1 human
macrophage cells (Additional file 1: Table S2). Plant
extracts, those having IC50 less than 2 μg/mL in antitry-
panosomal assay were Alnus rubra (0.94 μg/mL), Hoita
macrostachya (0.48 μg/mL), Salvia spathacea (1.13 μg/
mL), Sabal minor (1.06 μg/mL), Syzygium aqueum
(1.84 μg/mL), Rubus odoratus (1.95 μg/mL), Ribes mon-
tigenum (1.94 μg/mL), Quercus alba (1.42 μg/mL), Leea
rubra (1.62 μg/mL), Coccoloba pubescens (0.83 μg/mL),
Rhus integrifolia (0.50 μg/mL), and Nuphar luteum
(0.42 μg/mL). Eight additional plant extracts with IC50
in the range of 2.0- 2.5 μg/mL in antitrypanosomal
assay were Juniperus communis (2.40 μg/mL), Lepechi-
nia calycina (2.50 μg/mL), Salix caroliniana (2.24 μg/
mL), Arceuthobium occidentale (2.47 μg/mL), Medi-
nilla magnifica (2.25 μg/mL), Acer rubrum (2.06 μg/
mL), Pinus aristata (2.42 μg/mL), Hypericum hyperi-
coides (2.28 μg/mL) also represent new antitrypanoso-
mal leads (Additional file 1: Table S2).
The active extracts were investigated for reported
phytochemical and pharmacological activities. Alnus
rubra, the Red alder, is a deciduous broadleaf tree native
to western North America. It is the largest species of
alder in North America and one of the largest in the
world, reaching heights of 20–35 m. Native Americans
have used various plant parts of Alnus rubra medicinally
as a purgative, an emetic, for aching bones, headaches,
coughs, biliousness, stomach problems, scrofula sores,
tuberculosis, asthma, and eczema, and as a general
panacea [14]. Antifungal and antibiotic activities have
also been reported in Alnus rubra [15, 16]. Diarylheptenone
1-(3′,4’-dihydroxyphenyl)-7-(4''-hydroxyphenyl)-4-hepten-3
-one and 1,7-bis(P-hydroxyphenyl)-4-hepten-3-one were
isolated from Alnus rubra bark and their structures eluci-
dated by spectrometric techniques [17]. A few minor
diarylheptanoid glycosides namely, diarylheptanoid
(S)-1,7-bis-(4-hydroxyphenyl)-heptan-3-one-5-O-beta-
D-xylopyranoside, and two known compounds, 1,7-bis-
(3,4-dihydroxyphenyl)-heptan-3-one-5-O-beta-D-glucopy-
ranoside and platyphylloside were also isolated from Alnus
rubra bark [18]. Alnus rubra extract is a novel antitrypa-
nosomal lead. Hoita macrostachya is a species of legume
known by the common name Large Leather Root. It is
native to California and Baja California where it can be
found in moist areas of a number of habitat types. This is
a hairy, glandular perennial herb producing a tall, branch-
ing stem approaching two meters in maximum height.
The potent antitrypanosomal activity reported herein is
the first pharmacological activity reported in this plant.
No phytochemical data are available on Hoita macrosta-
chya. Therefore, this also represents a novel antitrypano-
somal lead. Sabal minor (Arecaceae), commonly known as
the Dwarf Palmetto or Bush palmetto, is one of about 14
species of Sabal palmetto palms. Native to the southeast-
ern United States, ranging from Florida north to eastern
North Carolina, and west to eastern Oklahoma and east-
ern Texas. Although it is mainly found in the southern
states, it is one of the only palms that can withstand some-
what cooler temperatures, and has been cultivated in
North and South Central Pennsylvania. This is the first re-
port regarding antitrypanosomal activity in this plant. No
phytochemical data are available on Sabal minor. Ribes
montigenum plant commonly known as mountain goose-
berry, alpine prickly currant, and gooseberry currant is
native to Western North America (British Columbia to
California to New Mexico). No previous phytochemical or
pharmacological results are reported in this plant. Cocco-
loba pubescens (Grandleaf Seagrape; syn. C. grandifolia,
also called “Eve’s Umbrella”) is a species of Coccoloba
native to coastal regions of the Caribbean, on Antigua,
Barbados, Barbuda, Dominica, Hispaniola, Martinique,
Montserrat, and Puerto Rico. No phytochemical or
pharmacological data are reported in this plant. Rhus
integrifolia, also known as Lemonade Berry or Lemonade
Sumac is a shrub to small tree. It is native to the Trans-
verse and Peninsular Ranges and the South Coast regions
of Southern California. This extends from Santa Barbara
County and the Channel Islands to San Diego County and
extending into north-central Pacific coastal Baja California
and its offshore islands such as Cedros Island. This is the
first report on any pharmacological activity in this plant.
No phytochemical data are available on Rhus integrifolia.
Nuphar lutea, the spatterdock, also known as yellow
water-lily, cow lily, or yellow pond-lily, is an aquatic plant
of the family Nymphaeaceae, native to Eurasia and North
America. It grows in eutrophic freshwater beds, with its
roots fixed into the ground and its leaves floating on the
water’s surface. Strong inhibition of NFkappaB activity
was found in extracts of leaf and rhizome from Nuphar
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lutea L. SM. (Nuphar). The inhibitory action was nar-
rowed down to a mixture of thionupharidines and/or
thionuphlutidines [19]. Antileishmanial activity has been
reported in partially purified alkaloid fraction (NUP) of
Nuphar lutea and dimeric sesquiterpene thioalkaloids
were identified as the major constituents of the mixture
[20]. The Nuphar lutea was identified as the most active
antitrypanosomal plant extract with IC50 0.42 μg/mL Few
additional plant extracts showed activity (IC50) in the
range of 2–10 μg/mL. Antioxidant activity has been re-
ported in extracts from Rhus hirta [21], a different species
of Rhus integrifolia (T. brucei IC50- 2.97 μg/mL), Juniperus
communis [22] (T. brucei IC50- 2.40 μg/mL) Sanguisorba
officinalis [23] (T. brucei IC50 3.56 μg/mL), Syzygium
malaccense [24] (T. brucei IC50 2.76 μg/mL) and Syzygium
aqueum [25] (T. brucei IC50 1.84 μg/mL). Eucalyptus
citriodora [26] (T. brucei IC50 3.34 μg/mL), Acer rubrum
[27] (T. brucei IC50 2.07 μg/mL), Yucca glauca [28] (T.
brucei IC50 3.56 μg/mL) plants have also been reported
for anticancer activity. Antiviral activity is reported in
Chamaecrista nictitans [29] (T. brucei IC50 5.76 μg/mL).
Antimicrobial activity is reported in Liriodendron tulipi-
fera [30] (T. brucei IC50 4.75 μg/mL) and Caesalpinia pul-
cherrima [31] (T. brucei IC50 4.76 μg/mL). Anthelminthic
activity is reported in Quercus alba [32] (T. brucei IC50
1.42 μg/mL).
Conclusions
In conclusion, the in vitro screening of 522 extracts, pre-
pared from plants collected from different parts of
North America, against blood stage form of T. brucei
has identified several plants extracts with potent antitry-
panosomal activity and no cytotoxicity against THP1
cells. The active plants extracts namely, Alnus rubra,
Hoita macrostachya, Salvia spathacea, Sabal minor, Ri-
bes montigenum, Quercus alba, Leea rubra, Coccoloba
pubescens, Rhus integrifolia and Nuphar luteum repre-
sent new antitrypanosomal leads. Most of the leadplant
extracts have very limited phytochemical and pharmaco-
logical data available. Further follow up studies with
these extracts are likely to provide novel compounds as
potential antitrypanosomal drug leads.
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